Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 18Carcinoma, Hepatocellular 18Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 12Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Advanced Solid Tumor 9Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Gemcitabine 115130-nm albumin-bound paclitaxel 66Albumin-Bound Paclitaxel 44Fluorouracil 37Magnetic Resonance Spectroscopy 35Irinotecan 35pembrolizumab 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 23Cyclophosphamide 21Nivolumab 18fludarabine 16Radiosurgery 16Cisplatin 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10Carboplatin 10Blood Specimen Collection 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × tislelizumab × 1 year × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Active not recruiting
25 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡